DOI: https://doi.org/10.22263/2312-4156.2022.4.29
T.V. Ryabtseva, A.D. Tahanovich, D.A. Makarevich
The assessment of TNF-α interaction with oligopeptide Trp-Asn-Trp-Val in vitro
Belarusian State Medical University, Minsk, Republic of Belarus
Vestnik VGMU. 2022;21(4):29-34.
Abstract.
The hyperproduction of TNF-α in the human body is a pathogenetic factor of many diseases development. The widespread clinical use of anticytokine drugs based on antibodies has a number of limitations. Therefore, the development of low molecular weight compounds for this cytokine blocking is a priority.
Objectives. To experimentally study the interaction of TNF-α with the synthetic oligopeptide Trp-Asn-Trp-Val, which is a structural analog of the soluble TNF-α receptor.
Material and methods. For registration of the interaction of the cytokine with oligopepetide the change in the concentration of TNF-α after its binding to the free and immobilized form of the oligopeptide was assessed. The immobilization of the oligopeptide was carried out by adsorption on the bottom of the well of a 96-well plate and incorporation of the peptide into a three-dimensional network of polyacrylamide gel. The concentration of TNF-α was determined by enzyme immunoassay.
The results of the study have shown that the dependence of the bound cytokine amount on its initial concentration is hyperbolic. The free form of the oligopeptide binds 6.8 (5.5; 8.1) pM/ml, adsorbed on the plate – 5.1 (4.3; 5.8) pM/ml of TNF-α. Immobilization of the oligopeptide in the gel significantly increases the ability of Trp-Asn-Trp-Val oligopeptide to bind TNF-α. The maximum concentration of TNF-α in blood plasma bound by the immobilized in gel peptide made up 16.8 (14.3; 19.2) pM/ml.
Thus, the conducted studies have shown that the oligopeptide Trp-Asn-Trp-Val, both in free and immobilized form, possesses a pronounced ability to bind TNF-α and may be used as a ligand for hemosorbents.
Keywords: tumor necrosis factor-alpha, oligopeptide, cytokines, systemic inflammatory response.
References
1. Aggarwal BB, Gupta SC, Kim JH. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood. 2012 Jan;119(3):651-65. doi: http://dx.doi.org/10.1182/blood-2011-04-325225
2. Kalliolias GD, Ivashkiv LB. TNF biology, pathogenic mechanisms and emerging therapeutic strategies. Nat Rev Rheumatol. 2016 Jan;12(1):49-62. doi: http://dx.doi.org/10.1038/nrrheum.2015.169
3. Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med. 1996 Jun;334(26):1717-25. doi: http://dx.doi.org/10.1056/NEJM199606273342607
4. Zulkarnaev AB, Vatazin AV, Pasov SA, Podoinitcyn AA. Modern concept of sepsis pathogenesis and promising approaches to its therapy (lecture). Al’m Klin Meditsiny. 2014;(30):91-8. (In Russ.)
5. Palladino MA, Bahjat FR, Theodorakis EA, Moldawer LL. Anti-TNF-a therapies: the next generation. Nat Rev Drug Discov. 2003 Sep;2(9):736-46. doi: http://dx.doi.org/10.1038/nrd1175
6. Tayal V, Kalra BS. Cytokines and anti-cytokines as therapeutics – an update. Eur J Pharmacol. 2008 Jan;579(1-3):1-12. doi: http://dx.doi.org/10.1016/j.ejphar.2007.10.049
7. Desai SB, Furst DE. Problems encountered during anti-tumor necrosis factor therapy. Best Pract Res Clin Rheumatol. 2006 Aug;20(4):757-90. doi: http://dx.doi.org/10.1016/j.berh.2006.06.002
8. Lau JL, Dunn MK. Therapeutic peptides: historical perspectives, current development trends, and future directions. Bioorganic Med Chem. 2017 Jul;26(10):2700-7. doi: http://dx.doi.org/10.1016/j.bmc.2017.06.052
9. Mascini M, Palchetti I, Tombelli S. Nucleic Acid and Peptide Aptamers: Fundamentals and Bioanalytical Aspects. Angew Chem Int Ed Engl. 2012 Feb;51(6):1316-32. doi: http://dx.doi.org/10.1002/anie.201006630
10. Menegatti S, Naik AD, Carbonell RG. The hidden potential of small synthetic molecules and peptides as affinity ligands for bioseparations. Pharm Bioprocess. 2013;1(5):467-85.
11. Riabtceva TV, Makarevich DA, Taganovich AD. Modeling and analysis of oligopeptide interaction with tumor necrosis factor-alpha. Ves Nats Akad Navuk Belarusі Ser Bіyal Navuk. 2021;66(4):453-461. (In Russ.) doi: http://dx.doi.org/10.29235/1029-8940-2021-66-4-453-461
12. Braitbard O, Glickstein H, Bishara-Shieban J, Pace U, Stein WD. Competition between bound and free peptides in an ELISA-based procedure that assays peptides derived from protein digests. Proteome Sci. 2006 May;4:12. doi: http://dx.doi.org/10.1186/1477-5956-4-12.
Information about authors:
T.V. Ryabtseva – research officer of the Research Department, postgraduate of the Chair of Biological Chemistry, Belarusian State Medical University,
E-mail: Этот адрес электронной почты защищён от спам-ботов. У вас должен быть включен JavaScript для просмотра. – Tatyana V. Ryabtseva;
A.D. Tahanovich – Doctor of Medical Sciences, professor, head of the Chair of Biological Chemistry, Belarusian State Medical University;
D.A. Makarevich – Candidate of Biological Sciences, leading researcher of the Research Department, Belarusian State Medical University.
